COPENHAGEN -
- Partnership to use Nuevolution’s Chemetics(R) Technology for Lead Discovery
Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis.
During the collaboration, Nuevolution will apply its proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against drug targets of interest to Novartis. The Chemetics(R) platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale.
Nuevolution will screen its multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics(R) follow-up libraries, the parties will also work together to perform hit-to-lead optimization.
Under the terms of the agreement, Novartis will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.
“We are delighted that Novartis has elected to enter this collaboration with Nuevolution” said Alex Gouliaev, CEO of Nuevolution A/S, and continued: “We look forward to an exciting and fruitful outcome of the collaboration.”
About Nuevolution
Nuevolution is a leading lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing lead discovery technologies.
Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.
Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Invest and Novo A/S. For more information about Nuevolution A/S, please visit the company’s website www.nuevolution.com
For further information about Nuevolution please contact: Nuevolution A/S Alex Haahr Gouliaev, CEO +45-3913-0987 ahg@nuevolution.com
Source: Nuevolution
For further information about Nuevolution please contact: Nuevolution A/S, Alex Haahr Gouliaev, CEO, +45-3913-0987, ahg at nuevolution.com
Related Press Releases
Astellas Pharma Europe Announces Winners of the Changing Tomorrow 2009 AwardsSeptember 22nd, 2009 STAINES, England - Astellas Pharma Europe Ltd., the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, has today announced the launch of the Astellas Changing Tomorrow Charity Awards. The charity award funding programme is designed to award organisations that help citizens of all communities realise their full potential and enhance their quality of life - both today and in the future.
Dutch Top Institute Pharma Attracts International InterestSeptember 9th, 2009 LEIDEN, The Netherlands - The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug PlatformAugust 23rd, 2009 CAMBRIDGE, Massachusetts -
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development.
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSKJuly 27th, 2009 COPENHAGEN, Denmark - Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline. The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads.
HRA Pharma Granted European Marketing Authorization for ellaOne(R)May 25th, 2009 PARIS - Next Generation Emergency Contraceptive Will First be Launched in UK, Germany and France as Company Expands International Operations
HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate), its next generation emergency contraceptive, has been granted marketing authorization by the European Commission. The unanimous decision by all member states enables HRA Pharma to begin marketing ellaOne throughout the European Union, making it the only approved product to have been specifically designed and developed for use as an emergency contraceptive.
Teikoku Pharma USA Acquires Travanti Pharma Inc.May 7th, 2009 SAN JOSE, California - Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body. The Company has developed a proprietary Wearable Electronic Disposable Drug delivery technology (WEDD(R)) Platform.
Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With GlaucomaMay 5th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA).
Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry EyeApril 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome.
Nuevolution Announces Progress in its Collaboration With Merck & Co. Inc.April 1st, 2009 COPENHAGEN - Nuevolution A/S today announced that Merck & Co. Inc. has chosen to proceed to the second phase of the collaboration agreement announced in June 2008 to apply Nuevolution's proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against several drug targets.
BioCis Pharma Starts Phase IIa Trial in PsoriasisMarch 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis.
Related News
Maxygen CEO and CFO to leave Wednesday as part of expanded partnership with Astellas PharmaSeptember 30th, 2009 Maxygen says CEO and CFO will leave Sept. 30NEW YORK — Maxygen Inc.
GVK Biosciences announces appointment of Gerhard N. Mayr to its Board of DirectorsAugust 4th, 2009 HYDERABAD - GVK Biosciences (GVK BIO) today announced the appointment of Gerhard N. Mayr to its Board of Directors.
Panjab University signs pact with Australian varsityJanuary 13th, 2009 CHANDIGARH - Panjab University (PU) signed an agreement on academic collaboration with the University of Western Australia (UWA) Wednesday. 'This collaboration will include both the staff and student exchange programmes and will facilitate the exchange of technical knowhow between the two institutions,' said B.S.
Delhi Tech University inks MoU with French consortiumSeptember 10th, 2009 NEW DELHI - The Delhi Technological University (DTU), formerly known as Delhi College of Engineering, Thursday inked a memorandum of understanding (MoU) with a network of seven French engineering institutions, The Groupe Des Ecoles Des Mines (GEM), to foster collaboration, provide opportunities for global experience and facilitate advancement of knowledge in the field of engineering. The MoU was signed here by DTU Vice Chancellor P.B.
Six million pounds for Indo-British science collaborationFebruary 2nd, 2009 LONDON - India and Britain Tuesday announced six million pounds of funding for large-scale science and technology collaboration between their universities and institutions. The three collaborations will be funded jointly by Research Councils UK (RCUK), a government-funded body, and the Indian Department of Science of Technology.
Neil Diamond 'planning collaboration with Fred Durst'April 8th, 2009 LONDON - Renowned pop legend Neil Diamond may end up matching tunes with Limp Bizkit rocker Fred Durst. The two got in touch using social networking site Twitter.com with Durst approaching the 68-year-old for a collaboration.
Southwest Bancorp announces quarterly dividend of 23.8 centsAugust 28th, 2009 Southwest Bancorp announces quarterly dividendSTILLWATER, Okla. — Southwest Bancorp Inc.
Emami to demerge realty, Zandu Pharma unitJune 19th, 2009 MUMBAI - The boards of Emami and Zandu Pharma have approved hiving off Emami's realty business into a separate firm, and merging Zandu's consumer goods (FMCG) unit with Emami, the companies said Friday. "The realty business of Emami will be now a separate company, Emami Infrastructure Ltd," Emami said in regulatory statement.
Four Gujarat pharma units found stashing used syringesMarch 6th, 2009 AHMEDABAD - In what could be termed an eye opener for other pollution control bodies across India, the Gujarat Pollution Control Board (GPCB) has so far found four pharmaceutical units near here storing used syringes and needles in their warehouses. Board officials raided the factories Thursday afternoon after being told by the Ahmedabad Municipal Corporation (AMC) about the possibility of the four pharma units in Naroda, Narol and Isanpur storing used syringes and needles.
Humidity Measurement Seminar to be held in Mumbai on April 3March 30th, 2009 MUMBAI - Jupiter Electronics, a leader in process control instruments and marketing pressure, temperature, humidity and air velocity sensors and transmitters will conduct a seminar on 'Humidity Measurement in Various Industries' on April 3. Ritler, Sales Manager, Rotronic A.
